- Home
- EMD vs NMRA Comparison
EMD vs NMRA Comparison
Compare EMD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EMD | NMRA |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 644.1M | 554.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | EMD | NMRA |
|---|---|---|
| Price | $10.27 | $2.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $6.57 |
| AVG Volume (30 Days) | 206.2K | ★ 784.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | ★ 57.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.56 | $0.62 |
| 52 Week High | $11.30 | $3.65 |
Technical Indicators
Market Signals| Indicator | EMD | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.94 | 38.01 |
| Support Level | $10.15 | $1.53 |
| Resistance Level | $10.40 | $2.93 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 12.74 | 7.92 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.